Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 5, 2011, Pages 829-837

  Huang, Yuxian ^a   Wang, Yang ^b   Li, Yuhua ^a   Guo, Kunyuan ^a   He, Yanjie ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

ABCG2; Natural killer (NK) cell; NKG2D NKG2DLs; Sorafenib; Sunitinib

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; DAUNORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN; NATURAL KILLER CELL RECEPTOR NKG2D; PACLITAXEL; SORAFENIB; SUNITINIB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZENESULFONATES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; GPI-LINKED PROTEINS; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY, ADOPTIVE; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LINEAR MODELS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PYRIDINES; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79955691460     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0944-2     Document Type: Article

References (24)

1. Bremers AJ, Parmiani G (2000) Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 34:1-25 (Pubitemid 30227314)
2. Chen XM, Xu XQ, Sun K, Hallett WH, Zhao JD, Zhang DL (2008) NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells. Scand Immunol 67:441-447 (Pubitemid 351519387)
3. Chrul S, Polakowska E, Szadkowska A, Bodalski J (2006) Influence of interleukin IL-2 and IL-12 + IL-18 on surface expression of immunoglobulin-like receptors KIR2DL1, KIR2DL2, and KIR3DL2 in natural killer cells. Mediators Inflamm 2006:46957
4. Forastiere AA (2008) Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol 97:701-707
5. Gasser S, Raulet DH (2006a) Activation and self-tolerance of natural killer cells. Immunol Rev 214:130-142 (Pubitemid 44707907)
6. Gasser S, Raulet DH (2006b) The DNA damage response arouses the immune system. Cancer Res 66(8):3959-3962
7. Guinn BA, Kasahara N, Farzaneh F, Habib NA, Norris JS, Deisseroth AB (2007) Recent advances and current challenges in tumor immunology and immunotherapy. Mol Ther 15:1065-1071 (Pubitemid 46813608)
8. Hiles JJ, Kolesar JM (2008) Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 65:123-131
9. Kancha RK, Grundler R, Peschel C, Duyster J (2007) Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol 35:1522-1526 (Pubitemid 47419140)
10. Larbcharoensub N, Leopairat J, Sirachainan E, Narkwong L, Bhongmakapat T, Rasmeepaisarn K, Janvilisri T (2008) Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. Hum Pathol 39:837-845
11. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib Blocks the RAF/MEK/ERK pathway inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858 (Pubitemid 46094197)
12. Ostberg JR, Dayance BE, Yuan M, Oflazoqlu E, Repasky EA (2007) Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J Leukoc Biol 82:1322-1331 (Pubitemid 350133530)
13. Pardoll DM (2001) Immunology Stress, NK receptors, and immune surveillance. Science 294:605-609
14. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178-6186 (Pubitemid 35244469)
15. Raguz S, Yagüe E (2000) Resistance to chemotherapy: new treatment and novel insights into an old problem. Br J Cancer 99:387-391
16. Robey RW, Polgar O, Deeken J, To KW, Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39-57 (Pubitemid 46452182)
17. Roda JM, Joshi T, Butchar JP, MaAlees JW, Lehman A, Tridandapani S, Carson WE (2007) The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 13:6420-6428
18. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosureillance and immunotherapy. Nat Immunol 2:293-299 (Pubitemid 33706339)
19. Song H, Kim J, Cosman D, Choi I (2006) Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 239:22-30 (Pubitemid 43927656)
20. Stuhler G, Walden P (2002) Cancer immune therapy, 3rd edn. Wiley, Berlin
21. Valés-Gómez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Revburn HT (2008) Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res 68:1546-1554 (Pubitemid 351346864)
22. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat immunol 9:503-510 (Pubitemid 351560519)
23. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732
24. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O'Reilly RJ (1998) Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 4:2859-2868 (Pubitemid 28523516)